1.81
price down icon4.23%   -0.08
after-market Handel nachbörslich: 1.80 -0.01 -0.55%
loading
Schlusskurs vom Vortag:
$1.89
Offen:
$1.96
24-Stunden-Volumen:
952.90K
Relative Volume:
1.71
Marktkapitalisierung:
$56.46M
Einnahmen:
$1.05M
Nettoeinkommen (Verlust:
$-48.82M
KGV:
-0.9891
EPS:
-1.83
Netto-Cashflow:
$-47.49M
1W Leistung:
+16.77%
1M Leistung:
+64.55%
6M Leistung:
+0.56%
1J Leistung:
-76.88%
1-Tages-Spanne:
Value
$1.76
$1.98
1-Wochen-Bereich:
Value
$1.40
$2.41
52-Wochen-Spanne:
Value
$1.06
$10.24

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name
Firmenname
Actinium Pharmaceuticals Inc
Name
Telefon
646-767-3870
Name
Adresse
275 Madison Avenue, 7th Floor, New York, NY
Name
Mitarbeiter
25
Name
Twitter
@actiniumpharma
Name
Nächster Verdiensttermin
2025-03-14
Name
Neueste SEC-Einreichungen
Name
ATNM's Discussions on Twitter

Vergleichen Sie ATNM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATNM
Actinium Pharmaceuticals Inc
1.81 56.46M 1.05M -48.82M -47.49M -1.83
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-07 Herabstufung B. Riley Securities Buy → Neutral
2024-05-14 Eingeleitet Stephens Overweight
2023-09-06 Eingeleitet HSBC Securities Buy
2023-02-21 Herabstufung William Blair Outperform → Mkt Perform
2022-09-08 Eingeleitet Cantor Fitzgerald Overweight
2022-08-25 Eingeleitet B. Riley Securities Buy
2020-11-05 Eingeleitet Alliance Global Partners Buy
2017-12-06 Eingeleitet B. Riley FBR, Inc. Buy
2017-10-23 Fortgesetzt ROTH Capital Buy
2017-09-14 Eingeleitet Maxim Group Buy
2016-08-25 Eingeleitet ROTH Capital Buy
2016-02-29 Eingeleitet H.C. Wainwright Buy
2015-10-15 Eingeleitet FBR Capital Outperform
2014-10-01 Eingeleitet MLV & Co Buy
2014-07-22 Eingeleitet Canaccord Genuity Buy
Alle ansehen

Actinium Pharmaceuticals Inc Aktie (ATNM) Neueste Nachrichten

pulisher
04:00 AM

ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView

04:00 AM
pulisher
08:23 AM

ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

08:23 AM
pulisher
08:17 AM

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - GlobeNewswire

08:17 AM
pulisher
08:00 AM

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesATNM - TradingView

08:00 AM
pulisher
Mar 29, 2025

ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Malaysian Reserve

Mar 29, 2025
pulisher
Mar 29, 2025

What is HC Wainwright’s Forecast for ATNM FY2027 Earnings? - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Indo-Asian News Service - IANS India Pvt Ltd

Mar 29, 2025
pulisher
Mar 28, 2025

ATNM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc. Investors - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit - PR Newswire

Mar 28, 2025
pulisher
Mar 28, 2025

Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire

Mar 28, 2025
pulisher
Mar 28, 2025

ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph

Mar 28, 2025
pulisher
Mar 28, 2025

ROSEN, A LEADING LAW FIRM, Encourages Actinium - GlobeNewswire

Mar 28, 2025
pulisher
Mar 28, 2025

ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider

Mar 28, 2025
pulisher
Mar 28, 2025

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Actinium Pharmaceuticals unveils non-PSMA-targeting Ac-225 radiotherapy for prostate cancer - BioWorld Online

Mar 28, 2025
pulisher
Mar 28, 2025

Actinium Pharmaceuticals ($ATNM) Misleading Trial Results and FDA Approval Case - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Actinium Pharmaceuticals secures Ac-225 supply from Eckert & Ziegler - DOTmed

Mar 28, 2025
pulisher
Mar 27, 2025

ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

Mar 27, 2025
pulisher
Mar 27, 2025

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) - Business Wire

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: New Prostate Cancer Treatment Achieves Near-Complete Tumor Elimination in Preclinical Study - StockTitan

Mar 27, 2025
pulisher
Mar 27, 2025

Actinium Pharmaceuticals unveils novel prostate cancer therapy - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing Cancer Treatment: Actinium's New Non-PSMA Therapy Targets $50B+ Market - StockTitan

Mar 27, 2025
pulisher
Mar 26, 2025

Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

Actinium rises ahead of presentation at Trump Mar-a-Lago Club - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Actinium stock rises ahead of Mar-a-Lago event (ATNM:NYSE) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today - PR Newswire

Mar 26, 2025
pulisher
Mar 26, 2025

Actinium Pharmaceuticals’ (ATNM) Buy Rating Reaffirmed at HC Wainwright - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Actinium (ATNM) Stock Gains Momentum Amid Key Investor Event - Stocks Telegraph

Mar 25, 2025
pulisher
Mar 25, 2025

Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - StockTitan

Mar 25, 2025
pulisher
Mar 24, 2025

Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities - PR Newswire

Mar 24, 2025
pulisher
Mar 24, 2025

Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateATNM - ACCESS Newswire

Mar 24, 2025
pulisher
Mar 20, 2025

Major Cancer Breakthrough: Actinium and MSK Join Forces to Transform AML Treatment Landscape - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy - PR Newswire

Mar 20, 2025
pulisher
Mar 19, 2025

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Cl - Longview News-Journal

Mar 19, 2025
pulisher
Mar 19, 2025

Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

Actinium Pharmaceuticals Launches Clinical Program to Evaluate Actimab-A as Combination Cancer Therapy - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO - Longview News-Journal

Mar 18, 2025
pulisher
Mar 17, 2025

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia - Longview News-Journal

Mar 17, 2025
pulisher
Mar 17, 2025

Game-Changing Leukemia Treatment Extends Survival 6x Longer Than Standard Therapy - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Analysts - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference - Citizentribune

Mar 12, 2025
pulisher
Mar 12, 2025

Leading Radiotherapy Company Actinium Opens Exclusive Investor Access at ROTH 2025 - StockTitan

Mar 12, 2025
pulisher
Mar 11, 2025

Actinium begins new Actimab-A trial combining Venetoclax and ASTX-727 to treat patients newly diagnosed with AML in partnership with NCI - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML - PR Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

Revolutionary Triple-Drug Combination Trial Targets Newly Diagnosed AML Patients - StockTitan

Mar 11, 2025
pulisher
Mar 03, 2025

Actinium Pharmaceuticals stock hits 52-week low at $1.07 By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 01, 2025

BriaCell Therapeutics (NASDAQ:BCTX) versus Actinium Pharmaceuticals (NYSE:ATNM) Critical Analysis - Defense World

Mar 01, 2025

Finanzdaten der Actinium Pharmaceuticals Inc-Aktie (ATNM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Kapitalisierung:     |  Volumen (24h):